The hepatitis C virus (HCV) envelope glycoprotein E1E2 complex is a candidate vaccine antigen. Previous immunization studies of E1E2 have yielded various results on its ability to induce virus-neutralizing antibodies in animal models and humans. The murine model has become a vital tool for HCV research owing to the development of humanized mice susceptible to HCV infec-tion. In this study, we investigated the antibody responses of mice immunized with E1E2 and a novel soluble form of E1E2 (sE1E2) by a DNA prime and protein boost strategy. The results showed that sE1E2 elicited higher antibody titers and a greater breadth of reactivity than the wild-type cell-associated E1E2. However, immune sera elicited by either immunogen were only weakly ...
<div><p>The hepatitis C virus (HCV) envelope glycoproteins E1 and E2 form a non-covalently linked he...
The mouse monoclonal antibody (MAb) AP33, recognizing a 12 amino acid linear epitope in the hepatiti...
Monoclonal antibodies (mAbs) targeting the hepatitis C virus (HCV) envelope have been raised mainly ...
Neutralizing antibody responses elicited during infection generally confer protection from infection...
Neutralizing antibody responses elicited during infection generally confer protection from infection...
Objective To find neutralizing antibody candidates against hepatitis C virus (HCV) infection. Met...
BACKGROUND & AIMS: Induction of cross-reactive antibodies targeting conserved epitopes of the envelo...
Induction of cross-reactive antibodies targeting conserved epitopes of the envelope proteins E1E2 is...
International audienceVarious strategies involving the use of hepatitis C virus (HCV) E1 and E2 enve...
Neutralizing antibodies have a role in controlling hepatitis C virus (HCV) infection. A successful v...
Hepatitis C virus (HCV) is a major cause of liver disease worldwide and there is a pressing need for...
A critical first step in a “rational vaccine design” approach for hepatitis C virus (HCV) is to iden...
It has been reported that monoclonal antibodies (MAbs) to the E1E2 glycoproteins may have the potent...
Evidence from clinical and experimental studies indicates that hepatitis C virus E2 (HCV/E2) glycopr...
It has been reported that monoclonal antibodies (MAbs) to the E1E2 glycoproteins may have the potent...
<div><p>The hepatitis C virus (HCV) envelope glycoproteins E1 and E2 form a non-covalently linked he...
The mouse monoclonal antibody (MAb) AP33, recognizing a 12 amino acid linear epitope in the hepatiti...
Monoclonal antibodies (mAbs) targeting the hepatitis C virus (HCV) envelope have been raised mainly ...
Neutralizing antibody responses elicited during infection generally confer protection from infection...
Neutralizing antibody responses elicited during infection generally confer protection from infection...
Objective To find neutralizing antibody candidates against hepatitis C virus (HCV) infection. Met...
BACKGROUND & AIMS: Induction of cross-reactive antibodies targeting conserved epitopes of the envelo...
Induction of cross-reactive antibodies targeting conserved epitopes of the envelope proteins E1E2 is...
International audienceVarious strategies involving the use of hepatitis C virus (HCV) E1 and E2 enve...
Neutralizing antibodies have a role in controlling hepatitis C virus (HCV) infection. A successful v...
Hepatitis C virus (HCV) is a major cause of liver disease worldwide and there is a pressing need for...
A critical first step in a “rational vaccine design” approach for hepatitis C virus (HCV) is to iden...
It has been reported that monoclonal antibodies (MAbs) to the E1E2 glycoproteins may have the potent...
Evidence from clinical and experimental studies indicates that hepatitis C virus E2 (HCV/E2) glycopr...
It has been reported that monoclonal antibodies (MAbs) to the E1E2 glycoproteins may have the potent...
<div><p>The hepatitis C virus (HCV) envelope glycoproteins E1 and E2 form a non-covalently linked he...
The mouse monoclonal antibody (MAb) AP33, recognizing a 12 amino acid linear epitope in the hepatiti...
Monoclonal antibodies (mAbs) targeting the hepatitis C virus (HCV) envelope have been raised mainly ...